A capital-light route into a US$31 billion market

Amplia Therapeutics has secured a clinical collaboration with pharmaceutical heavyweight Eli Lilly, a deal that hands the small Melbourne biotech a foothold in lung cancer without draining its modest balance sheet. Announced to the ASX on 4 August 2026, the agreement will see Amplia's experimental focal adhesion kinase (FAK) inhibitor, narmafotinib, tested alongside Lilly's investigational KRAS G12C inhibitor, olomorasib, in patients with advanced non-small cell lung cancer (NSCLC).

For a company whose lead programme has, until now, been anchored in pancreatic cancer, the tie-up marks a deliberate widening of ambition. It also carries the imprimatur of one of the world's largest drug developers at a point when Amplia's market value sits at roughly A$62 million, a fraction of Lilly's. The arrangement is structured as a clinical trial collaboration and supply agreement rather than a licensing transaction or equity investment, a distinction that matters for how investors should read it.

What Amplia actually signed

Under the terms disclosed, Amplia will sponsor and run a Phase 1b/2b study combining narmafotinib with olomorasib as a second-line treatment for advanced NSCLC. Trial sites are planned across Australia and the United States, with the study expected to begin in late 2026 once the protocol and associated documentation are finalised.

Crucially, Lilly's contribution is the in-kind supply of olomorasib rather than cash. That makes the collaboration capital-efficient for Amplia, which avoids paying for a second, late-stage drug candidate to populate the combination arm. No upfront payments, milestones or royalty terms were disclosed, and Amplia has not handed Lilly any rights over narmafotinib. In practical terms, Amplia keeps ownership of its asset and the trial data while sharing the scientific risk of the combination.

This is an important nuance. A supply-and-collaboration agreement is a long way from the kind of licensing deal or takeover that can transform a micro-cap's valuation overnight. What Amplia has gained is validation, access to a clinically advanced partner drug, and a lower-cost way to open a second cancer indication. What it has not gained is a cheque or a guaranteed commercial partner.

The science: hitting cancer's escape routes

The logic behind pairing the two drugs rests on how tumours evade targeted therapy. KRAS G12C is one of the most common cancer-driving mutations in NSCLC, present in roughly 13 per cent of patients. Drugs that block it, such as olomorasib, can shrink tumours, but the benefit is frequently short-lived as cancers rewire their signalling and grow resistant.

FAK, the target of narmafotinib, sits within that web of resistance signalling and in the surrounding tumour microenvironment. The theory, supported by preclinical work from Amplia and others, is that inhibiting FAK at the same time as KRAS may blunt the escape mechanisms and make responses deeper and more durable. Olomorasib is itself no minor asset: Lilly already has it enrolled in two global Phase III NSCLC studies, which is part of why the collaboration lends narmafotinib credibility.

Chris Burns, Amplia's chief executive, framed the deal as "an exciting new stage in the clinical progression of narmafotinib", noting that the company and others have shown the combination of FAK and KRAS inhibition can lead to improved outcomes. That is a hypothesis the new trial is designed to test, not an established result, and investors should treat it as such.

Why the pancreatic data underpins the pitch

Amplia's confidence draws heavily on its ACCENT study, a Phase 1b/2a trial in first-line advanced pancreatic cancer that pairs narmafotinib with the chemotherapy backbone of gemcitabine and nab-paclitaxel. Pancreatic cancer is among the deadliest of solid tumours, and the results reported through 2026 have been the company's calling card.

As of its March 2026 update, ACCENT had delivered an objective response rate of 35.9 per cent across 64 evaluable patients, including five complete responses, a 7.8 per cent complete-response rate the company describes as unusually high for the disease. Median overall survival was reported at 11.1 months, around two months better than chemotherapy alone, with interim progression-free survival previously reported at about 7.6 months. The trial, run across sites in Australia and South Korea, is expected to complete in the third quarter of 2026.

That tolerability and efficacy signal is what gives narmafotinib a plausible case as a combination partner. It is worth stressing, however, that pancreatic cancer response data does not automatically translate to lung cancer, and the ACCENT trial remains relatively small and single-armed.

Strategic and financial significance

For Amplia, the strategic value lies in diversification. Betting a clinical-stage biotech on a single indication is precarious; opening a second, well-funded shot on goal in a far larger market spreads that risk. The NSCLC opportunity is substantial, with the global market estimated at around US$31 billion and forecast by some analysts to exceed US$60 billion by 2033.

The financial reality is more sober. Amplia is a loss-making pre-revenue company that has repeatedly returned to the market to raise capital, and running a Phase 1b/2b lung cancer trial alongside its pancreatic and ovarian programmes will consume cash even with Lilly supplying the partner drug. The quality of the collaboration does not change the fundamental need to fund operations, and shareholders should watch the cash position and any capital raisings closely.

Risks, unknowns and what comes next

Several uncertainties temper the enthusiasm. The trial has not yet started, no financial terms were attached, and Lilly retains no obligation beyond supplying its drug for this study; the pharma giant could walk away from any deeper relationship. Early-phase oncology trials also carry a high failure rate, and combination studies can surface unexpected toxicity that single agents do not.

The near-term catalysts worth tracking are the finalisation of the trial protocol, confirmation of the first sites and patient dosing in late 2026, the Q3 2026 completion of the ACCENT pancreatic study, and any read-through from Lilly's own Phase III olomorasib programmes. Progress on Amplia's funding runway will be just as important as clinical milestones.

The Lilly collaboration is a genuine vote of confidence and a shrewd, low-cost way for Amplia to enter lung cancer. But it is a starting line, not a finish. The value on offer depends entirely on whether the combination can convert scientific rationale into durable responses in patients, and that answer is still years away.